$CELC
Celcuity Inc

2019 Q1 Form 10-K Financial Statement

#000114420419011631 Filed on March 01, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 2017 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $380.0K $1.610M $420.0K
YoY Change -28.3% 65.98% 500.0%
% of Gross Profit
Research & Development $1.591M $6.326M $1.400M
YoY Change 2.93% 27.02% 66.67%
% of Gross Profit
Depreciation & Amortization $76.17K $223.0K $20.00K
YoY Change 91.68% 113.02% 0.0%
% of Gross Profit
Operating Expenses $1.975M $7.933M $1.820M
YoY Change -4.9% 33.25% 100.0%
Operating Profit -$1.975M -$7.933M
YoY Change -4.9% 33.25%
Interest Expense $43.00 $111.00 $100.0K
YoY Change -99.98%
% of Operating Profit
Other Income/Expense, Net $128.6K $451.7K
YoY Change 18.67% -251.19%
Pretax Income -$1.846M -$7.481M -$1.720M
YoY Change -6.2% 19.66% 91.11%
Income Tax $0.00 $0.00 $370.0K
% Of Pretax Income
Net Earnings -$1.846M -$7.481M -$1.720M
YoY Change -6.2% 19.66% 91.11%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$181.4K -$739.1K -$170.1K
COMMON SHARES
Basic Shares Outstanding 10.21M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $23.42M $24.90M $24.20M
YoY Change 1.83% 2.89%
Cash & Equivalents $14.72M $15.94M $2.640M
Short-Term Investments $8.700M $8.950M $21.56M
Other Short-Term Assets $340.0K $320.0K $290.0K
YoY Change 3.03% 10.34%
Inventory
Prepaid Expenses $287.8K $209.7K
Receivables
Other Receivables
Total Short-Term Assets $23.76M $25.22M $24.48M
YoY Change 1.86% 3.02% 314.14%
LONG-TERM ASSETS
Property, Plant & Equipment $862.2K $810.0K $280.1K
YoY Change 94.37% 189.29% 93.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $7.210M
YoY Change -100.0%
Other Assets
YoY Change
Total Long-Term Assets $1.178M $810.0K $7.485M
YoY Change -84.08% -89.19% 5065.5%
TOTAL ASSETS
Total Short-Term Assets $23.76M $25.22M $24.48M
Total Long-Term Assets $1.178M $810.0K $7.485M
Total Assets $24.94M $26.03M $31.97M
YoY Change -18.83% -18.58% 427.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $208.9K $120.0K $71.91K
YoY Change 60.65% 71.43% -78.31%
Accrued Expenses $485.2K $470.0K $506.1K
YoY Change -25.7% -7.84% 344.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $10.00K $10.00K
YoY Change
Total Short-Term Liabilities $882.2K $660.0K $578.1K
YoY Change 12.66% 13.79% 29.79%
LONG-TERM LIABILITIES
Long-Term Debt $20.00K $20.00K $0.00
YoY Change
Other Long-Term Liabilities $180.0K
YoY Change
Total Long-Term Liabilities $200.0K $20.00K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $882.2K $660.0K $578.1K
Total Long-Term Liabilities $200.0K $20.00K $0.00
Total Liabilities $1.077M $680.0K $578.1K
YoY Change 37.57% 17.24% 29.79%
SHAREHOLDERS EQUITY
Retained Earnings -$11.33M -$2.007M
YoY Change 185.12% -75.91%
Common Stock $10.21K $10.09K
YoY Change 1.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $23.86M $25.35M $31.39M
YoY Change
Total Liabilities & Shareholders Equity $24.94M $26.03M $31.97M
YoY Change -18.83% -18.58% 427.81%

Cashflow Statement

Concept 2019 Q1 2018 2017 Q4
OPERATING ACTIVITIES
Net Income -$1.846M -$7.481M -$1.720M
YoY Change -6.2% 19.66% 91.11%
Depreciation, Depletion And Amortization $76.17K $223.0K $20.00K
YoY Change 91.68% 113.02% 0.0%
Cash From Operating Activities -$1.590M -$6.076M -$1.110M
YoY Change 9.84% 22.8% 56.34%
INVESTING ACTIVITIES
Capital Expenditures $47.64K $629.6K -$40.00K
YoY Change -76.68% 162.5% 300.0%
Acquisitions
YoY Change
Other Investing Activities $250.0K $19.72M -$28.49M
YoY Change -82.14% -168.62%
Cash From Investing Activities $197.4K $19.09M -$28.53M
YoY Change -83.51% -165.9% 285200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 172.2K 236.7K -20.00K
YoY Change -6.27% -99.23%
NET CHANGE
Cash From Operating Activities -1.590M -6.076M -1.110M
Cash From Investing Activities 197.4K 19.09M -28.53M
Cash From Financing Activities 172.2K 236.7K -20.00K
Net Change In Cash -1.220M 13.25M -29.66M
YoY Change 1718.0% -512.08% 4019.44%
FREE CASH FLOW
Cash From Operating Activities -$1.590M -$6.076M -$1.110M
Capital Expenditures $47.64K $629.6K -$40.00K
Free Cash Flow -$1.638M -$6.706M -$1.070M
YoY Change -0.86% 29.26% 52.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 dei Document Type
DocumentType
10-K
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
31391457
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Entity Registrant Name
EntityRegistrantName
Celcuity Inc.
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
10087
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
34827467
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
33388597
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9488042
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2007227
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
25349611
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26031821
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31969510
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6325995
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001603454
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2018Q2 dei Entity Public Float
EntityPublicFloat
142809688
CY2018 dei Trading Symbol
TradingSymbol
CELC
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10209115
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
8952907
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
21556857
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
0
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
50000
CY2018Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
22009
CY2017Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
27726
CY2018Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
28743
CY2017Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
0
CY2018Q4 us-gaap Assets Current
AssetsCurrent
25218208
CY2017Q4 us-gaap Assets Current
AssetsCurrent
24484080
CY2018Q4 us-gaap Long Term Investments
LongTermInvestments
0
CY2017Q4 us-gaap Long Term Investments
LongTermInvestments
7205374
CY2018Q4 us-gaap Assets
Assets
26031821
CY2017Q4 us-gaap Assets
Assets
31969510
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
119811
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
71913
CY2018Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
5730
CY2017Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
0
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
536791
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
506140
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
662332
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
578053
CY2018Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
19878
CY2017Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
0
CY2018Q4 us-gaap Liabilities
Liabilities
682210
CY2017Q4 us-gaap Liabilities
Liabilities
578053
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
10186
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-5952945
CY2018 us-gaap Interest Expense
InterestExpense
111
CY2017 us-gaap Interest Expense
InterestExpense
451664
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
448834
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4980427
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1606543
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
972518
CY2018 us-gaap Operating Expenses
OperatingExpenses
7932538
CY2017 us-gaap Operating Expenses
OperatingExpenses
5952945
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-7932538
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
152879
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
451723
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-298785
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7480815
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6251730
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
874386
CY2018 us-gaap Other Noncash Expense
OtherNoncashExpense
0
CY2017 us-gaap Other Noncash Expense
OtherNoncashExpense
451664
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
54514
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
231717
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.84
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10124544
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7460640
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-7480815
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-6251730
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
1168616
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
25432
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-262507
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-44349
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
392315
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6076269
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4947982
CY2018 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
3235000
CY2017 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
28737135
CY2018 us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
22955000
CY2017 us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
0
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
629608
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
239848
CY2018 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
4000
CY2017 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19094392
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-28976983
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
183759
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2052
CY2018 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
141732
CY2017 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
0
CY2018 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2017 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
7493330
CY2018 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2017 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
24109650
CY2018 celc Payments For Registration Statement Costs
PaymentsForRegistrationStatementCosts
27443
CY2017 celc Payments For Registration Statement Costs
PaymentsForRegistrationStatementCosts
0
CY2018 celc Payments For Capital Leases
PaymentsForCapitalLeases
3324
CY2017 celc Payments For Capital Leases
PaymentsForCapitalLeases
0
CY2018 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
CY2017 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
40961
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2889
CY2017 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
855665
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
236697
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30708406
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
13254820
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3216559
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5906348
CY2018Q4 us-gaap Held To Maturity Securities Amortized Cost Before Other Than Temporary Impairment
HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment
8952907
CY2017Q4 us-gaap Held To Maturity Securities Amortized Cost Before Other Than Temporary Impairment
HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment
28762231
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
353980
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
373323
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
224125
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
162914
CY2018Q4 us-gaap Prepaid Rent
PrepaidRent
21490
CY2017Q4 us-gaap Prepaid Rent
PrepaidRent
21673
CY2018Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
24325
CY2017Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
25121
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
269940
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
209708
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1294510
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
540175
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
480897
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
260119
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
813613
CY2018Q4 celc Accrued Compensation
AccruedCompensation
391629
CY2017Q4 celc Accrued Compensation
AccruedCompensation
451631
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
63875
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
0
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
280056
CY2018 us-gaap Depreciation
Depreciation
223037
CY2017 us-gaap Depreciation
Depreciation
104704
CY2018Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
28940
CY2017Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
32533
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
52347
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
21976
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
173367
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
193338
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
64940
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
431645
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
125324
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
51455
CY2018 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
200000
CY2017 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
350000
CY2018Q4 us-gaap Contractual Obligation
ContractualObligation
2690000
CY2018Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
28932
CY2018Q4 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
3375
CY2018Q4 us-gaap Capital Leases Balance Sheet Assets By Major Class Net
CapitalLeasesBalanceSheetAssetsByMajorClassNet
25557
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
7255
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
7255
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
7255
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
7255
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
3022
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
32042
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
401
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Executory Costs
CapitalLeasesFutureMinimumPaymentsExecutoryCosts
6033
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
25608
CY2018Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
353980
CY2017Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
373323
CY2018 celc Investment Warrant Exercise Price
InvestmentWarrantExercisePrice
9.42
CY2018Q4 celc Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Not Yet Recognizedremainder Of Fiscal Year
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedremainderOfFiscalYear
776145
CY2018Q4 celc Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Not Yet Recognizedwithin Two Years
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedwithinTwoYears
477676
CY2018Q4 celc Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Not Yet Recognizedwithin Three Years
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedwithinThreeYears
302387
CY2018Q4 celc Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Not Yet Recognizedwithin Four Years
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedwithinFourYears
117538
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1673746
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
2571
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
2571
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
5250
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
0
CY2017Q2 celc Proceeds From Issuance Of Convertible Debt Gross
ProceedsFromIssuanceOfConvertibleDebtGross
8337500
CY2017Q2 celc Debt Insrtument Commission Percentage
DebtInsrtumentCommissionPercentage
0.1
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1571000
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-682000
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-30000
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-130000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1881000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
897000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-280000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
3000
CY2018 celc Income Tax Reconciliation Revaluation Of Deferred Tax Due Tax Reform
IncomeTaxReconciliationRevaluationOfDeferredTaxDueTaxReform
0
CY2017 celc Income Tax Reconciliation Revaluation Of Deferred Tax Due Tax Reform
IncomeTaxReconciliationRevaluationOfDeferredTaxDueTaxReform
366000
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-454000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
45000000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
14000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
112000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
329000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
325000
CY2018Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
103000
CY2017Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
68000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1067000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
392000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2778000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
897000
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10186382
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10087516
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10186382
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10087516
CY2018 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
3000
CY2018 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
3000
CY2017 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2018 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-89324
CY2017 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
25097
CY2018 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
55138
CY2017 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
CY2018Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
50000
CY2018Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15944609
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2639789
CY2018Q4 us-gaap Restricted Cash
RestrictedCash
0
CY2017Q4 us-gaap Restricted Cash
RestrictedCash
50000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15944609
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2689789
CY2018 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
24055
CY2017 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0
CY2018 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
28932
CY2017 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0
CY2018 celc Leasehold Improvements Funded By Landlord And Related Deferred Rent Included In Accrued Expenses
LeaseholdImprovementsFundedByLandlordAndRelatedDeferredRentIncludedInAccruedExpenses
75000
CY2017 celc Leasehold Improvements Funded By Landlord And Related Deferred Rent Included In Accrued Expenses
LeaseholdImprovementsFundedByLandlordAndRelatedDeferredRentIncludedInAccruedExpenses
0
CY2018 celc Registration Statement Costs Included In Accounts Payable
RegistrationStatementCostsIncludedInAccountsPayable
1300
CY2017 celc Registration Statement Costs Included In Accounts Payable
RegistrationStatementCostsIncludedInAccountsPayable
0
CY2018 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0
CY2017 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
844170
CY2018 celc Debt Discount Related To Investor And Agent Warrant
DebtDiscountRelatedToInvestorAndAgentWarrant
0
CY2017 celc Debt Discount Related To Investor And Agent Warrant
DebtDiscountRelatedToInvestorAndAgentWarrant
1063715
CY2018 celc Deferred Transaction Costs Included In Accounts Payable And Accrued Expenses
DeferredTransactionCostsIncludedInAccountsPayableAndAccruedExpenses
0
CY2017 celc Deferred Transaction Costs Included In Accounts Payable And Accrued Expenses
DeferredTransactionCostsIncludedInAccountsPayableAndAccruedExpenses
2889
CY2018 celc Ipo Costs Reduced In Cash Proceeds
IpoCostsReducedInCashProceeds
0
CY2017 celc Ipo Costs Reduced In Cash Proceeds
IpoCostsReducedInCashProceeds
275000
CY2018Q4 celc Contractual Obligation Due For Future Payment
ContractualObligationDueForFuturePayment
32000
CY2018Q4 celc Contractual Obligation Future Obligation Milestones
ContractualObligationFutureObligationMilestones
150000
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;"><div style="font-weight:bold;display:inline;">Accounting Estimates</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Management uses estimates and assumptions in preparing these financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the valuation of stock-based compensation and warrants issued to investors, a placement agent and an underwriter, and prepaid or accrued clinical trial costs.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;"><div style="font-weight:bold;display:inline;">Risks and Uncertainties</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its diagnostic tests, ability to obtain regulatory approval of its diagnostic tests, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
at a conversion ratio of 40 Units for one share of Common Stock.
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.750
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
5250
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
0
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
618550
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
5611618
CY2017 celc Adjustments To Additional Paid In Capital Warrant Issued To Unsecured Convertible Promissory Note Holders
AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToUnsecuredConvertiblePromissoryNoteHolders
776717
CY2017 celc Adjustments To Additional Paid In Capital Warrant Issued To Placement Agent
AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToPlacementAgent
286999
CY2017 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
0
CY2017 celc Stock Issued Convertible Conversion Of Common Stock Value
StockIssuedConvertibleConversionOfCommonStockValue
0
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
22466986
CY2017 celc Adjustments To Additional Paid In Capital Warrant Issued To Underwriter
AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToUnderwriter
784111
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
6840318
CY2017 celc Stock Issued During Period Value Upon Exercise Of Warrants
StockIssuedDuringPeriodValueUponExerciseOfWarrants
2052
CY2017 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
677371
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
197015
CY2018 celc Stock Issued During Period Value Upon Exercise Of Warrants
StockIssuedDuringPeriodValueUponExerciseOfWarrants
183759
CY2018 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
1024152
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
144464
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
141732
CY2016 celc Warrants Expiration Period
WarrantsExpirationPeriod
P10Y
CY2018Q4 celc Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Startup Expenditures
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures
1265000
CY2017Q4 celc Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Startup Expenditures
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures
0
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21

Files In Submission

Name View Source Status
0001144204-19-011631-index-headers.html Edgar Link pending
0001144204-19-011631-index.html Edgar Link pending
0001144204-19-011631.txt Edgar Link pending
0001144204-19-011631-xbrl.zip Edgar Link pending
celc-20181231.xml Edgar Link completed
celc-20181231.xsd Edgar Link pending
celc-20181231_cal.xml Edgar Link unprocessable
celc-20181231_def.xml Edgar Link unprocessable
celc-20181231_lab.xml Edgar Link unprocessable
celc-20181231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv514491_10k.htm Edgar Link pending
tv514491_ex23-1.htm Edgar Link pending
tv514491_ex31-1.htm Edgar Link pending
tv514491_ex31-2.htm Edgar Link pending
tv514491_ex32-1.htm Edgar Link pending
tv514491_ex32-2.htm Edgar Link pending